What Happens If You Drink on Acamprosate?

Drinking alcohol while taking acamprosate does not trigger a dangerous physical reaction, and it does not change how drunk you feel or how quickly your body processes alcohol. This sets acamprosate apart from disulfiram (Antabuse), which deliberately makes you sick if you drink. Acamprosate works differently: it quietly dials down cravings in the background, and research suggests it keeps doing useful work even if you have a slip. That said, the picture is more nuanced than “nothing happens,” and understanding what the medication is actually doing can change how you think about a lapse.

No Violent Reaction, No Change in How Alcohol Hits You

The most important thing to know is that acamprosate will not make you vomit, flush, or feel dangerously ill if you drink. People sometimes confuse it with disulfiram, which blocks an enzyme involved in alcohol metabolism and causes intense nausea, headache, and heart pounding within minutes of drinking. Acamprosate does nothing like that. A controlled dose-response study in humans found that acamprosate did not alter alcohol’s pharmacokinetics or the behavioral impairment and increased heart rate that alcohol normally produces, and most of the subjective effects of drinking were also unchanged.¹ In plain terms, if you take acamprosate and then have a beer, that beer will affect you the same way it would without the medication. You will not get drunk faster or slower, and you will not experience any punishment effect.

This is by design. Acamprosate was never meant to deter drinking through unpleasant consequences. Its purpose is to reduce the internal drive that pulls a person back toward alcohol after they have stopped. If a lapse happens, the medication has not failed in the way people often assume.

What Acamprosate Is Actually Doing in Your Brain

Chronic heavy drinking reshapes how your brain’s signaling systems work. One of the most affected systems involves glutamate, the brain’s primary excitatory chemical messenger. Over time, the brain compensates for alcohol’s sedating effects by ramping up glutamate activity. When you stop drinking, that excess glutamate activity does not immediately calm down. The result is a hyperexcitable state that can feel like anxiety, restlessness, irritability, and an intense pull back toward alcohol to quiet things down.

Acamprosate targets this imbalance. It modulates a specific type of glutamate receptor and may also have indirect effects on inhibitory signaling. Studies in both animals and humans show that it decreases brain glutamate levels and increases beta-endorphins.² The practical effect is that the medication takes the edge off the neurological distress that drives many people back to drinking. Researchers have described this as targeting “relief craving,” the desire to drink not for pleasure but to escape the tension and discomfort of early sobriety.³

What Happens to Cravings After a Slip

Here is where the story gets interesting for anyone worried about drinking while on acamprosate. One of the well-known risks in recovery is the “priming effect,” where a single drink triggers an intense desire for more. A small amount of alcohol acts like a signal to the brain that the reward is available, and cravings can surge. A randomized controlled trial specifically tested whether acamprosate could blunt this priming response. Patients on acamprosate who were given a standard priming drink experienced significantly less craving afterward compared to those on placebo. The study also found that acamprosate reduced the spike in cortisol (a stress hormone) that alcohol normally triggers, and that higher blood levels of acamprosate correlated with lower craving following the priming drink.⁴

This matters practically. If you are taking acamprosate and you have a drink at a party, the medication may reduce the likelihood that one drink turns into five. The pull to keep going after that first sip is blunted. This does not mean drinking is safe or advisable while on acamprosate, but it does mean the medication is working in a way that is specifically designed to help limit the damage of a slip.

Should You Stop Taking It If You Relapse?

A common instinct after drinking is to stop taking the medication, either out of guilt, a sense that “it’s not working,” or a misunderstanding of how it functions. This is generally the wrong call. Because acamprosate does not interact dangerously with alcohol and continues to reduce cravings even when alcohol is present, most treatment guidelines advise patients to keep taking it through a lapse. The medication’s value is not binary: it does not only work during perfect abstinence and then become useless the moment you drink. Its craving-reduction properties remain active and can help you get back on track faster.

The clinical evidence supports this approach. In a large trial, patients on acamprosate achieved a continuous abstinence rate of 43% over the treatment period compared to 21% for placebo, and they were abstinent for a significantly greater share of days overall.⁵ The key word is “continuous.” Not everyone maintained perfect sobriety, but the overall trajectory was better. Stopping the medication after a lapse removes a tool that is still actively helping.

Timing Matters More Than You Might Think

One area where the research delivers a somewhat counterintuitive finding involves when acamprosate is started. A study that randomized patients to begin acamprosate either during detoxification or after it found no significant benefit from starting early. In fact, patients who received acamprosate during detox actually had somewhat worse drinking outcomes in the rehabilitation phase that followed, including more heavy drinking days and more drinks per drinking day compared to those who started on placebo during detox.⁶

The reasons for this are not entirely settled, but the finding suggests that acamprosate works best once the brain has had a chance to begin stabilizing after acute withdrawal. Starting it too early, while alcohol may still be in the system and while the brain is in its most chaotic state, does not appear to help and may even confuse the picture. If you are in the process of detoxing and wondering whether to start acamprosate right away, this is worth discussing with your doctor.

How Acamprosate Differs from Naltrexone

People prescribed medication for alcohol dependence often encounter two main options: acamprosate and naltrexone. The two drugs work through entirely different mechanisms, and understanding the difference matters if you are worried about what happens when you drink.

Naltrexone blocks opioid receptors and is thought to reduce the pleasurable, rewarding feelings alcohol produces. Its primary target is what researchers call “reward craving,” the pull toward drinking because it feels good. Acamprosate, as discussed earlier, targets “relief craving,” the pull toward drinking to escape discomfort.³ In practical terms, naltrexone makes drinking less fun, while acamprosate makes not drinking less painful. Neither causes the dramatic sickness that disulfiram produces.

The two medications can be combined. A study of the four possible treatment strategies (naltrexone alone, acamprosate alone, both together, and placebo) found no serious medical adverse events across any group. Side effects were generally mild. The combination did increase rates of diarrhea (about 14% versus 7% with acamprosate alone) and nausea (about 6% versus under 1% with acamprosate alone), but these were manageable.⁷ Combining the two did not create any dangerous interaction with alcohol itself.

Typical Side Effects With and Without Drinking

Acamprosate’s side effect profile is relatively mild regardless of whether you drink. The most commonly reported issue is diarrhea, which tends to appear early in treatment and often fades with time. In the comparative trial mentioned above, about 7% of patients taking acamprosate alone reported diarrhea, which was on par with the placebo rate.⁷ Other reported effects include bloating, fatigue, and skin reactions, though these led to treatment discontinuation in only a handful of participants across the entire study.

Drinking does not worsen these side effects in any documented way. The human dose-response study that tested acamprosate alongside alcohol administration did not find that the combination amplified any adverse reactions.¹ You might feel the usual effects of alcohol (impaired coordination, slowed thinking, nausea if you drink too much) and the usual effects of acamprosate (mild gastrointestinal issues), but the two do not appear to compound each other into something worse.

One important caveat: acamprosate is eliminated through the kidneys, not the liver. This means it is generally considered safe for people with liver disease, which is common among heavy drinkers. However, anyone with significant kidney problems should use it cautiously or not at all, since the drug can accumulate if the kidneys cannot clear it properly.

Neuroprotection During Vulnerable Periods

Beyond craving reduction, acamprosate appears to offer a secondary benefit that is especially relevant when someone relapses. Chronic alcohol use followed by withdrawal creates a toxic cycle for brain cells. During withdrawal, the surge of glutamate activity can damage neurons through a process called excitotoxicity, where nerve cells are essentially overstimulated to the point of injury or death. This may contribute to the cognitive decline and brain tissue loss sometimes seen in long-term alcohol dependence.⁸

Laboratory research suggests acamprosate can block this excitotoxicity. In studies using rat brain cells that had been exposed to alcohol, acamprosate protected the neurons against glutamate-induced damage more effectively than it protected unexposed neurons, suggesting the drug is particularly helpful in brains that have been primed by alcohol.⁹ This is animal and cell-culture data, not a proven clinical benefit in humans, but it raises the possibility that staying on acamprosate even through a relapse could protect your brain from some of the neurological harm that repeated drinking-and-withdrawal cycles cause.

What Biomarker Testing Reveals About Real-World Use

One study used urinary biomarkers to track actual drinking behavior among patients prescribed acamprosate in an outpatient setting. On the first day, about 65% of acamprosate patients and 78% of placebo patients tested positive for recent drinking. By day 22, those numbers had dropped to about 30% in the acamprosate group and 33% in the placebo group. Both groups improved significantly from their starting points, but the difference between acamprosate and placebo was not statistically significant in this particular study.¹⁰

This finding is worth putting in context. The study was relatively small and short in duration. Larger, longer trials have shown more robust benefits for acamprosate over placebo, as noted in the trial showing 43% versus 21% continuous abstinence rates. But the biomarker study does highlight something important: many patients in real-world treatment are drinking, at least early on. The question is not really whether drinking ever happens on acamprosate. It does, frequently. The question is whether the medication changes the trajectory, and the broader evidence suggests it does, particularly over months rather than weeks.

Acamprosate in Pregnancy

For women who become pregnant while on acamprosate, the limited available evidence is cautiously reassuring. A scoping review of both human and animal research on alcohol pharmacotherapies in pregnancy found that acamprosate was not clearly associated with adverse effects during pregnancy, and two preclinical studies even suggested potential neuroprotective properties for the developing brain.¹¹

A population-level study from New South Wales, Australia, found that hospital admissions during pregnancy among acamprosate-treated women were not significantly different from the general community, and that birth weight, rates of small-for-gestational-age neonates, and congenital abnormalities (including fetal alcohol syndrome) were comparable across groups.¹² A mouse study further found that acamprosate exposure did not affect mating success, litter size, neonatal body measurements, or most neurodevelopmental markers, and it appeared to mitigate some negative effects of alcohol on offspring development.¹³

This does not mean acamprosate is recommended in pregnancy. The evidence base remains thin, and no major clinical guideline currently endorses its routine use during pregnancy. But for a woman who has been taking it and discovers she is pregnant, or for whom the risks of untreated alcohol dependence during pregnancy are severe, these findings suggest the medication itself is not an obvious source of fetal harm. The decision belongs to the patient and her physician, weighed against the well-documented harms of heavy drinking during pregnancy.